This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00050/identifier/wikipedia/
n11http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00050/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n20http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00050/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00050/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/patent/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00050/identifier/national-drug-code-directory/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n27http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00050/identifier/chebi/
n16http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00050
rdf:type
n3:Drug
n3:description
Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.
n3:dosage
n24:271B41C3-363D-11E5-9242-09173F13E4C5 n24:271B41C4-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
~62.8 hours
n3:indication
For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation
n3:manufacturer
n9:271B41C0-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00050 n20:DB00050
dcterms:title
Cetrorelix
adms:identifier
n19:DB00050 n21:59224 n22:D01685 n23:44087-1225-1 n25:PA164764506 n26:Cetrorelix
n3:mechanismOfAction
Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.
n3:packager
n9:271B41BF-363D-11E5-9242-09173F13E4C5 n9:271B41BD-363D-11E5-9242-09173F13E4C5 n9:271B41BE-363D-11E5-9242-09173F13E4C5
n3:patent
n17:5198533 n17:2115943 n17:6319192
n3:routeOfElimination
Following subcutaneous administration of 10 mg cetrorelix to males and females, only unchanged cetrorelix was detected in urine.
n3:synonym
Cetrorelixum
n3:volumeOfDistribution
* 1.16 L/kg
n10:hasAHFSCode
n11:92-00-00
n3:proteinBinding
86%
n3:salt
n6:hasConcept
n7:M0173811
foaf:page
n13:cetrorelix-acetate.html n27:cetrorelix.htm
n3:IUPAC-Name
n4:271B41C9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B41CF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B41CE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B41CB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B41CC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B41CD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B41C7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B41C5-363D-11E5-9242-09173F13E4C5 n4:271B41C8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B41C6-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n16:H01CC02
n3:H-Bond-Acceptor-Count
n4:271B41D5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B41D6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B41D0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B41D1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B41D3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B41D2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B41D4-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
120287-85-6
n3:category
n3:clearance
* 1.28 ml/min·kg [adult healthy female with 3 mg single SC administration]
n3:containedIn
n5:271B41C2-363D-11E5-9242-09173F13E4C5 n5:271B41C1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B41DB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B41DD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B41DE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B41DA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B41D9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B41DC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B41CA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B41D7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B41D8-363D-11E5-9242-09173F13E4C5